EE04356B1 - aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis - Google Patents

aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis

Info

Publication number
EE04356B1
EE04356B1 EEP200100154A EEP200100154A EE04356B1 EE 04356 B1 EE04356 B1 EE 04356B1 EE P200100154 A EEP200100154 A EE P200100154A EE P200100154 A EEP200100154 A EE P200100154A EE 04356 B1 EE04356 B1 EE 04356B1
Authority
EE
Estonia
Prior art keywords
inhibitor
diabetes
treatment
pharmaceutical composition
pravastatin
Prior art date
Application number
EEP200100154A
Other languages
English (en)
Estonian (et)
Inventor
A. Robl Jeffrey
A. Biller Scott
A. Parker Rex
Jamil Haris
L. Jacobson Bruce
Kodukula Krishna
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200100154A publication Critical patent/EE200100154A/xx
Publication of EE04356B1 publication Critical patent/EE04356B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
EEP200100154A 1998-09-17 1999-09-13 aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis EE04356B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17
PCT/US1999/020946 WO2000015229A1 (en) 1998-09-17 1999-09-13 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (2)

Publication Number Publication Date
EE200100154A EE200100154A (et) 2002-12-16
EE04356B1 true EE04356B1 (et) 2004-10-15

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200100154A EE04356B1 (et) 1998-09-17 1999-09-13 aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
EEP200100155A EE200100155A (et) 1998-09-17 1999-09-13 Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200100155A EE200100155A (et) 1998-09-17 1999-09-13 Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni

Country Status (30)

Country Link
US (1) US20020035064A1 (de)
EP (2) EP1121129B1 (de)
JP (2) JP2002524518A (de)
KR (2) KR20010079842A (de)
CN (2) CN1319012A (de)
AT (1) ATE406898T1 (de)
AU (2) AU755563B2 (de)
BG (2) BG105431A (de)
BR (2) BR9913833A (de)
CA (2) CA2344300A1 (de)
CO (2) CO5130026A1 (de)
CZ (2) CZ2001965A3 (de)
DE (1) DE69939481D1 (de)
EE (2) EE04356B1 (de)
ES (1) ES2311306T3 (de)
GE (2) GEP20033044B (de)
HU (2) HUP0104240A2 (de)
ID (2) ID27833A (de)
IL (2) IL141785A0 (de)
LT (2) LT4870B (de)
LV (2) LV12686B (de)
NO (2) NO20011352L (de)
NZ (2) NZ510207A (de)
PE (2) PE20001056A1 (de)
PL (2) PL346661A1 (de)
SK (1) SK3202001A3 (de)
TR (2) TR200100773T2 (de)
UY (2) UY25714A1 (de)
WO (2) WO2000015230A1 (de)
ZA (2) ZA200207433B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047423B1 (de) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Aptoptoseinhibitoren
CA2361335A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1253925A1 (de) 2000-01-28 2002-11-06 Bristol-Myers Squibb Company Tetrahydropyrimidinon-inhibitoren von fettsäure bindenden proteinen und verfahren
JP2004536023A (ja) * 2000-11-20 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー ａＰ２インヒビターとしてのピリドン誘導体
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
WO2003006023A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Company Pyrazinone inhibitors of fatty acid binding protein and method
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20070043512A1 (en) * 2003-03-26 2007-02-22 Michael Rolph Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
AU2005221656B2 (en) 2004-03-05 2011-06-23 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
PT1756064E (pt) 2004-06-04 2008-07-22 Merck & Co Inc Derivados de pirazole, composições contendo tais compostos e métodos de utilização
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP1919882A2 (de) 2005-02-17 2008-05-14 Synta Pharmaceuticals Corporation Isoxazol-combretastatin-derivate zur behandlung proliferativer erkrankungen
EP1910303A2 (de) 2005-07-26 2008-04-16 Merck & Co., Inc. Verfahren zur synthese eines substituierten pyrazols
WO2007047725A2 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
JP2012508692A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
SI2403605T1 (sl) 2009-03-05 2015-11-30 President And Fellows Of Harvard College Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
JP7038707B2 (ja) * 2016-06-27 2022-03-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 代謝障害の治療に有用な化合物
WO2018227200A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
US12084419B2 (en) 2020-06-27 2024-09-10 Crescenta Biosciences Cell metabolism modulating compounds and uses thereof
CN116322682A (zh) 2020-07-29 2023-06-23 艾米琳制药有限责任公司 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (de) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
AU610591B2 (en) 1987-05-22 1991-05-23 E.R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DE69425162T2 (de) * 1993-12-20 2000-12-21 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazol-derivate
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
LT2001022A (en) 2001-08-27
CZ2001964A3 (cs) 2002-01-16
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
ZA200207430B (en) 2003-09-16
CN1319012A (zh) 2001-10-24
PE20001056A1 (es) 2000-12-24
AU754488B2 (en) 2002-11-14
LT4870B (lt) 2001-12-27
ID27833A (id) 2001-04-26
CA2344300A1 (en) 2000-03-23
IL141785A0 (en) 2002-03-10
BR9913833A (pt) 2001-05-29
ID28450A (id) 2001-05-24
NZ510209A (en) 2003-07-25
EP1121129A1 (de) 2001-08-08
JP2002524517A (ja) 2002-08-06
CN1317970A (zh) 2001-10-17
LV12687B (lv) 2001-10-20
TR200100774T2 (tr) 2001-12-21
GEP20033044B (en) 2003-08-25
ATE406898T1 (de) 2008-09-15
IL141786A0 (en) 2002-03-10
SK3202001A3 (en) 2002-04-04
PE20001047A1 (es) 2000-12-24
KR20010075150A (ko) 2001-08-09
LT2001023A (en) 2001-08-27
ES2311306T3 (es) 2009-02-01
CO5130026A1 (es) 2002-02-27
WO2000015229A1 (en) 2000-03-23
NO20011352D0 (no) 2001-03-16
AU6143799A (en) 2000-04-03
UY25714A1 (es) 2001-08-27
EE200100154A (et) 2002-12-16
NO20011351L (no) 2001-05-11
US20020035064A1 (en) 2002-03-21
LV12686A (en) 2001-07-20
JP2002524518A (ja) 2002-08-06
EE200100155A (et) 2002-08-15
EP1113801A4 (de) 2002-10-02
ZA200207433B (en) 2003-10-27
WO2000015230A1 (en) 2000-03-23
TR200100773T2 (tr) 2001-07-23
HUP0104240A2 (hu) 2002-03-28
AU755563B2 (en) 2002-12-12
GEP20033045B (en) 2003-08-25
NO20011352L (no) 2001-05-11
KR20010079842A (ko) 2001-08-22
NO20011351D0 (no) 2001-03-16
BR9913831A (pt) 2001-05-29
UY25713A1 (es) 2001-08-27
LV12687A (en) 2001-07-20
HUP0104108A2 (hu) 2002-03-28
CA2344309A1 (en) 2000-03-23
PL346660A1 (en) 2002-02-25
NZ510207A (en) 2003-08-29
EP1113801A1 (de) 2001-07-11
EP1121129A4 (de) 2002-10-16
DE69939481D1 (de) 2008-10-16
CO5130025A1 (es) 2002-02-27
EP1121129B1 (de) 2008-09-03
AU6387799A (en) 2000-04-03
PL346661A1 (en) 2002-02-25
CZ2001965A3 (cs) 2002-02-13
BG105432A (en) 2001-12-29
BG105431A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
EA200400149A1 (ru) Бензотиепины, обладающие активностью ингибиторов перемещения желчных кислот в подвздошной кишке и поглощения таурохолата
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
DE69801661D1 (de) Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
WO1998018440A3 (fr) Utilisation des inhibiteurs de l&#39;activite de l&#39;acide retinoique pour traiter les peaux sensibles
IL124236A (en) Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
MY140504A (en) Statin-mmp inhibitor combinations
NO963989D0 (no) Hypokolesterolemiske-, antiatherosklerotiske- og hypotriglyceridemiske mercaptoacetylamidderivater
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
BR0112460A (pt) Método para tratamento de sépsis
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
TH48054A3 (th) วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
BR9502969A (pt) Composto de espirostanil-glicosideo método para o tratamento de hipercolesterolomia composição farmacêutica e método para o tratamento de atersclerose

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20040913